A user's progress in treating their hair loss with Finasteride, Minoxidil and Dermarolling; they discussed details of their routine and others congratulated them on their success.
A 36-year-old switched from Finasteride to Dutasteride after 6 years due to thinning hair, adding oral Minoxidil for regrowth. Dutasteride improved hair thickness with fewer side effects, while Finasteride caused anxiety and back pain.
User ordered oral minoxidil, dutasteride, and a derma roller for hair loss treatment. Others encouraged patience and shared positive experiences with similar treatments.
The user experienced side effects from finasteride and is considering adding Alfatradiol or Fluridil to their regimen, which includes Minoxidil, dermarolling, and ketoconazole. Fluridil is noted to be more effective than Alfatradiol but less effective than finasteride, with mild side effects reported.
The user shared their positive experience with hair regrowth using dutasteride, initially combined with minoxidil, noting significant improvement in hair thickness and hairline over 1.5 years. They stopped minoxidil due to its greasiness but continued with dutasteride every other day, experiencing manageable shedding and no serious side effects.
A user's success in treating their hair loss with 2x daily topical dutasteride and minoxidil, as well as the potential for using less frequent application of topical dutasteride due to its long half-life.
The user experienced significant hair regrowth using 0.5mg dutasteride and 5mg oral minoxidil, with fewer side effects compared to finasteride. They noticed improvements in hair thickness and hairline, despite intermittent use of performance-enhancing substances.
RU58841 is discussed for hair loss treatment, with questions about its legitimacy from RUdirect. Minoxidil and finasteride are also mentioned as treatments.
Topical Dutasteride may halt hair loss and effectively treat androgenic alopecia. Combining low-dose oral Dutasteride with topical application could maximize regrowth and minimize side effects.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.